SOURCE: Syneron Medical Ltd.

Syneron Medical Ltd.

June 21, 2011 09:00 ET

Syneron Medical Provides Updated Estimate of Loss Contingency Associated With Palomar Litigation

Reduces Estimated Range From $0 to $50 Million to a Range of $0 to $21 Million

YOKNEAM, ISRAEL--(Marketwire - Jun 21, 2011) - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that it has adjusted its estimate of the range of loss contingency associated with litigation between Palomar Medical Technologies, Inc. (NASDAQ: PMTI) and Syneron's subsidiary, Candela Corporation, from $0 to $50 million as set forth in the notes to its consolidated financial statements as of December 31, 2010, to a range of $0 to $21 million. Syneron's determination that contingent losses related to the Palomar proceedings are only reasonably possible remains unchanged, therefore it continues not to record any accrual for the loss contingency.

The adjusted estimate is based on the April 26, 2011 summary judgment decision of the District Court in Massachusetts and a recent submission by Palomar regarding its damage claim, which indicated that because the remaining patent claim at issue is a method claim, the royalty base for Candela's accused products is limited to sales of those products in the United States.

Shimon Eckhouse, Chairman of Board of Syneron, stated, "Palomar's amended damage report provides affirmation that the recent summary judgment from the District Court was a major victory for Candela. It confirms that Palomar does not have legal grounds to seek royalty damages for international sales, significantly reducing Candela's potential financial exposure in the litigation. Furthermore, we remain confident that the single remaining Palomar claim, method claim 32 of the '844 patent, will be defeated at trial once the facts are presented in Court."

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets and services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.

Contact Information

  • Contacts:

    Asaf Alperovitz
    Chief Financial Officer
    + 972 73 244 2283
    Email: Email Contact

    Nick Laudico
    The Ruth Group
    Email: Email Contact

    Zack Kubow
    The Ruth Group
    Email: Email Contact